Terms: = Thyroid cancer AND CCDC6, D10S170, 8030, ENSG00000108091, Q16204, TPC, H4, TST1 AND Prognosis
40 results:
1. AKR1C3 silencing inhibits autophagy-dependent glycolysis in thyroid cancer cells by inactivating ERK signaling.
Gao Y; Tao W; Wang S; Duan R; Zhang Z
Drug Dev Res; 2024 Feb; 85(1):e22142. PubMed ID: 38349266
[TBL] [Abstract] [Full Text] [Related]
2. Clinical value of multi-gene testing in distinguishing benign and malignant thyroid nodules.
Zhang M; Hu X; Liu L; Wang Y; Jiang J; Li H; Fei W; Zhong T; Jiang Z
Medicine (Baltimore); 2024 Jan; 103(4):e35960. PubMed ID: 38277563
[TBL] [Abstract] [Full Text] [Related]
3. MEX3A induces the development of thyroid cancer via targeting CREB1.
Feng G; Wang P; Zhang H; Cheng S; Xing Y; Wang Y
Cell Biol Int; 2023 Nov; 47(11):1843-1853. PubMed ID: 37529875
[TBL] [Abstract] [Full Text] [Related]
4. Clinical Impact of Androgen Receptor-Suppressing miR-146b Expression in Papillary thyroid cancer Aggressiveness.
Chou CK; Chi SY; Hung YY; Yang YC; Fu HC; Wang JH; Chen CC; Kang HY
J Clin Endocrinol Metab; 2023 Oct; 108(11):2852-2861. PubMed ID: 37220080
[TBL] [Abstract] [Full Text] [Related]
5. MicroRNA-130a-3p impedes the progression of papillary thyroid carcinoma through downregulation of KPNB1 by targeting PSME3.
Wang Y; Xu J; Zhu X; Kuang H
Endocrine; 2023 Oct; 82(1):96-107. PubMed ID: 37166548
[TBL] [Abstract] [Full Text] [Related]
6. TESC promotes differentiated thyroid cancer development by activating ERK and weakening NIS and radioiodine uptake.
Guo Y; Cai Y; Song F; Zhu L; Hu Y; Liu Y; Ma W; Ge J; Zeng Q; Ding L; Li L; Zheng G; Ge M
Endocrine; 2023 Sep; 81(3):503-512. PubMed ID: 37020077
[TBL] [Abstract] [Full Text] [Related]
7. Three-dimensional genome landscape comprehensively reveals patterns of spatial gene regulation in papillary and anaplastic thyroid cancers: a study using representative cell lines for each cancer type.
Zhang L; Xu M; Zhang W; Zhu C; Cui Z; Fu H; Ma Y; Huang S; Cui J; Liang S; Huang L; Wang H
Cell Mol Biol Lett; 2023 Jan; 28(1):1. PubMed ID: 36609218
[TBL] [Abstract] [Full Text] [Related]
8. An integrative pan cancer analysis of RET aberrations and their potential clinical implications.
Zhou L; Li J; Zhang X; Xu Z; Yan Y; Hu K
Sci Rep; 2022 Aug; 12(1):13913. PubMed ID: 35978072
[TBL] [Abstract] [Full Text] [Related]
9. NOD1 activation promotes cell apoptosis in papillary thyroid cancer.
Bai N; Liu C; Zhang X; Cheng Y; Hou D
Pathol Res Pract; 2022 May; 233():153880. PubMed ID: 35430507
[TBL] [Abstract] [Full Text] [Related]
10. Machine learning algorithms are comparable to conventional regression models in predicting distant metastasis of follicular thyroid carcinoma.
Mao Y; Lan H; Lin W; Liang J; Huang H; Li L; Wen J; Chen G
Clin Endocrinol (Oxf); 2023 Jan; 98(1):98-109. PubMed ID: 35171531
[TBL] [Abstract] [Full Text] [Related]
11. MicroRNA-99a-3p/GRP94 axis affects metastatic progression of human papillary thyroid carcinoma by regulating ITGA2 expression and localization.
Gao Y; Pan Y; Wang T; Yao Y; Yuan W; Zhu X; Wang K
Acta Biochim Biophys Sin (Shanghai); 2021 Dec; 53(12):1650-1661. PubMed ID: 34687203
[TBL] [Abstract] [Full Text] [Related]
12. A 6 transcription factors-associated nomogram predicts the recurrence-free survival of thyroid papillary carcinoma.
Wang T; Tian K; Ji X; Song F
Medicine (Baltimore); 2021 Oct; 100(40):e27308. PubMed ID: 34622829
[TBL] [Abstract] [Full Text] [Related]
13. Diverse Oncogenic Fusions and Distinct Gene Expression Patterns Define the Genomic Landscape of Pediatric Papillary thyroid Carcinoma.
Stosic A; Fuligni F; Anderson ND; Davidson S; de Borja R; Acker M; Forte V; Campisi P; Propst EJ; Wolter NE; Chami R; Mete O; Malkin D; Shlien A; Wasserman JD
Cancer Res; 2021 Nov; 81(22):5625-5637. PubMed ID: 34535459
[TBL] [Abstract] [Full Text] [Related]
14. Comprehensive analysis of pan-cancer reveals potential of ASF1B as a prognostic and immunological biomarker.
Hu X; Zhu H; Zhang X; He X; Xu X
Cancer Med; 2021 Oct; 10(19):6897-6916. PubMed ID: 34472711
[TBL] [Abstract] [Full Text] [Related]
15. miR-1301-3p suppresses tumor growth by downregulating PCNA in thyroid papillary cancer.
Qiao DH; He XM; Yang H; Zhou Y; Deng X; Cheng L; Zhou XY
Am J Otolaryngol; 2021; 42(2):102920. PubMed ID: 33454555
[TBL] [Abstract] [Full Text] [Related]
16. DPP4 gene silencing inhibits proliferation and epithelial-mesenchymal transition of papillary thyroid carcinoma cells through suppression of the MAPK pathway.
Hu X; Chen S; Xie C; Li Z; Wu Z; You Z
J Endocrinol Invest; 2021 Aug; 44(8):1609-1623. PubMed ID: 33387351
[TBL] [Abstract] [Full Text] [Related]
17. MicroRNA-198 inhibits metastasis of thyroid cancer by targeting H3F3A.
Fang J; Zhu JM; Dai HL; He LM; Kong L
Eur Rev Med Pharmacol Sci; 2020 Dec; 24(23):12232-12240. PubMed ID: 33336742
[TBL] [Abstract] [Full Text] [Related]
18. M2-like tumor-associated macrophages-secreted Wnt1 and Wnt3a promotes dedifferentiation and metastasis via activating β-catenin pathway in thyroid cancer.
Lv J; Feng ZP; Chen FK; Liu C; Jia L; Liu PJ; Yang CZ; Hou F; Deng ZY
Mol Carcinog; 2021 Jan; 60(1):25-37. PubMed ID: 33283877
[TBL] [Abstract] [Full Text] [Related]
19. A methylomics-associated nomogram predicts recurrence-free survival of thyroid papillary carcinoma.
Chen H; Ma X; Yang M; Wang M; Li L; Huang T
Cancer Med; 2020 Oct; 9(19):7183-7193. PubMed ID: 32783399
[TBL] [Abstract] [Full Text] [Related]
20. Propofol suppresses migration, invasion, and epithelial-mesenchymal transition in papillary thyroid carcinoma cells by regulating miR-122 expression.
Li Y; Zeng QG; Qiu JL; Pang T; Wang H; Zhang XX
Eur Rev Med Pharmacol Sci; 2020 May; 24(9):5101-5110. PubMed ID: 32432774
[TBL] [Abstract] [Full Text] [Related]
[Next]
